The Thorough QT/QTc Study of TS-071 in Healthy Subjects

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222303

Enrollment

Registered

2013-11-21

Start date

2013-11-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese subjects

Interventions

investigational material(s) Generic name etc : TS-071 INN of investigational material : luseogliflozin Therapeutic category code : 396 Antidiabetic agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy Japanese subjects etc.

Exclusion criteria

Exclusion criteria: The subject has hepatic/biliary, respiratory, cardiovascular, gastrointestinal, urological, renal, endocrine or immunological disorder, malignant tumor, diabetes mellitus or impaired glucose tolerance etc.

Design outcomes

Secondary

Measure	Time frame
QTcB, QT interval corrected by Bazett's formula, etc.	—

Primary

Measure	Time frame
QTcF	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026